Neoadjuvant disitamab vedotin plus carboplatin in HER2-expressing advanced ovarian cancer: A prospective, single-arm, phase II trial.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2026-05-27
DOI
https://doi.org/10.1200/jco.2026.44.16_suppl.5556
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Neoadjuvant disitamab vedotin plus carboplatin in HER2-expressing advanced ovarian cancer: A prospective, single-arm, phase II trial.

Qiaqia Li, Yifan Meng, T Wan, Wei Wei et al.
Journal of Clinical Oncology
HER2/EGFR in Cancer Research
article

Neoadjuvant disitamab vedotin plus carboplatin in HER2-expressing advanced ovarian cancer: A prospective, single-arm, phase II trial.

Qiaqia Li, Yifan Meng, T Wan, Wei Wei, Jundong Li, Fan Yang
article en

Abstract

No abstract available for this paper.
Journal of Clinical OncologyVol. 44(16_suppl)
Sun Yat-sen University (CN), Sun Yat-sen University Cancer Center (CN), State Key Laboratory of Oncology in South China
Openalex Percentile: Top 11%
HER2/EGFR in Cancer Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.